Investors


Investor R&D Day

Dear Immunomedics Investors and Analysts,

You are cordially invited to attend the Immunomedics Investor R&D Day on Wednesday, January 18, 2017, at The Roosevelt Hotel, 45 E 45th St, New York, NY 10017 (between Madison and Vanderbilt Avenues in New York City) beginning at 9 a.m. Eastern Time.

We are already making progress in 2017 and look forward to sharing new data with you during the event.

To confirm your attendance and register for the conference, please email Chau Cheng at ccheng@Immunomedics.com, (973) 605-8200 ext 7-123 with your name, title and firm name or fill out this RSVP form .

Please RSVP no later than 5 p.m. Eastern Time, January 17, 2017. Only individuals who register will be able to attend, and we ask that you confirm any guests you intend to bring by providing the same information.

We hope to see you at our R&D Day and look forward to speaking with you further over the coming weeks to discuss the Company’s continued progress toward significant value creation for stockholders.

If you have questions regarding registration for Investor R&D Day, please contact Chau Cheng.

Thank you for your continued support and for your continued investment in Immunomedics.

Disclaimer

This webpage, in addition to historical information, may contain forward-looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding clinical trials, out-licensing arrangements (including the timing and amount of contingent payments), forecasts of future operating results, potential collaborations, and capital raising activities, involve significant risks and uncertainties and actual results could differ materially from those expressed or implied herein.

Factors that could cause such differences include, but are not limited to, risks associated with new product development (including clinical trials outcome and regulatory requirements/actions), our dependence on our licensing partners for the further development of epratuzumab for autoimmune indications and veltuzumab for non-cancer indications, competitive risks to marketed products and availability of required financing and other sources of funds on acceptable terms, if at all, as well as the risks discussed in the Company’s filings with the Securities and Exchange Commission. The Company is not under any obligation, and the Company expressly disclaims any obligation, to update or alter any forward-looking statements, whether as a result of new information, future events or otherwise.